US drugmaker Eli Lilly and Company will invest more than $1 billion in India over the next few years, as it looks to expand manufacturing and strengthen supply chains for some of its key medicines. The company will work with local contract manufacturers and set up a new Manufacturing and Quality hub in Hyderabad to oversee production.
Hiring for the Hyderabad facility will begin immediately, with roles open for engineers, chemists, analytical scientists and quality specialists. Lilly said the hub will support its wider global manufacturing network and ensure a steady supply of medicines for conditions such as diabetes, obesity, Alzheimer’s, cancer and autoimmune diseases.
Patrik Jonsson, president of Lilly International, said the investment was part of the company’s effort to build global capacity. “We are making significant investments to increase manufacturing and medicine supply capacity around the world. India will play an important role in supporting our evolving portfolio,” he said.
The move comes after Lilly launched its weight-loss and diabetes drug Mounjaro in India earlier this year, a treatment that has seen strong global demand. Analysts say the investment will help the company secure long-term supply at a time of intensifying competition in the obesity drug market.
Telangana Chief Minister A. Revanth Reddy welcomed the announcement, saying it highlighted Hyderabad’s growing importance in global healthcare. Industries Minister Sridhar Babu also pointed to the state’s focus on technology-led growth and ease of doing business as a draw for multinational drugmakers.
Be the first to comment